International Cancer of the Pancreas Screening (CAPS) Consortium summit on the management of patients with increased risk for familial pancreatic cancer

Background Screening individuals at increased risk for pancreatic cancer (PC) detects early, potentially curable, pancreatic neoplasia. Objective To develop consortium statements on screening, surveillance and management of high-risk individuals with an inherited predisposition to PC. Methods A 49-expert multidisciplinary international consortium met to discuss pancreatic screening and vote on statements. Consensus was considered reached if ≥75% agreed or disagreed. Results There was excellent agreement that, to be successful, a screening programme should detect and treat T1N0M0 margin-negative PC and high-grade dysplastic precursor lesions (pancreatic intraepithelial neoplasia and intraductal papillary mucinous neoplasm). It was agreed that the following were candidates for screening: first-degree relatives (FDRs) of patients with PC from a familial PC kindred with at least two affected FDRs; patients with Peutz–Jeghers syndrome; and p16, BRCA2 and hereditary non-polyposis colorectal cancer (HNPCC) mutation carriers with ≥1 affected FDR. Consensus was not reached for the age to initiate screening or stop surveillance. It was agreed that initial screening should include endoscopic ultrasonography (EUS) and/or MRI/magnetic resonance cholangiopancreatography not CT or endoscopic retrograde cholangiopancreatography. There was no consensus on the need for EUS fine-needle aspiration to evaluate cysts. There was disagreement on optimal screening modalities and intervals for follow-up imaging. When surgery is recommended it should be performed at a high-volume centre. There was great disagreement as to which screening abnormalities were of sufficient concern to for surgery to be recommended. Conclusions Screening is recommended for high-risk individuals, but more evidence is needed, particularly for how to manage patients with detected lesions. Screening and subsequent management should take place at high-volume centres with multidisciplinary teams, preferably within research protocols.

[1]  Jin-Young Jang,et al.  International consensus guidelines 2012 for the management of IPMN and MCN of the pancreas. , 2012, Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.].

[2]  Zhe Zhang,et al.  Frequent detection of pancreatic lesions in asymptomatic high-risk individuals. , 2012, Gastroenterology.

[3]  Aung Ko Win,et al.  Colorectal and other cancer risks for carriers and noncarriers from families with a DNA mismatch repair gene mutation: a prospective cohort study. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  A. Zauber,et al.  Colonoscopic polypectomy and long-term prevention of colorectal-cancer deaths. , 2012, The New England journal of medicine.

[5]  E. Kuipers,et al.  Routine testing for PALB2 mutations in familial pancreatic cancer families and breast cancer families with pancreatic cancer is not indicated , 2011, European Journal of Human Genetics.

[6]  M. Haider,et al.  Screening for Pancreatic Cancer in a High-Risk Cohort: An Eight-Year Experience , 2012, Journal of Gastrointestinal Surgery.

[7]  W. Brugge,et al.  Cyst Fluid Carcinoembryonic Antigen Is an Accurate Diagnostic Marker of Pancreatic Mucinous Cysts , 2011, Pancreas.

[8]  V. Lemmens,et al.  Improving outcome for patients with pancreatic cancer through centralization , 2011, The British journal of surgery.

[9]  A. Maitra,et al.  Recurrent GNAS Mutations Define an Unexpected Pathway for Pancreatic Cyst Development , 2011, Science Translational Medicine.

[10]  S. Stättner,et al.  TNM stage and grade in predicting the prognosis of operated, non‐functioning neuroendocrine carcinoma of the pancreas—a single‐institution experience , 2011, Journal of surgical oncology.

[11]  J. Birkmeyer,et al.  Trends in hospital volume and operative mortality for high-risk surgery. , 2011, The New England journal of medicine.

[12]  J. Cameron,et al.  Presence of Pancreatic Intraepithelial Neoplasia in the Pancreatic Transection Margin does not Influence Outcome in Patients with R0 Resected Pancreatic Cancer , 2011, Annals of Surgical Oncology.

[13]  T. Brentnall.  Editorial: Pancreatic Cancer Surveillance: Learning As We Go , 2011, The American Journal of Gastroenterology.

[14]  W. Jarnagin,et al.  Feasibility and Yield of Screening in Relatives From Familial Pancreatic Cancer Families , 2011, The American Journal of Gastroenterology.

[15]  R. Hruban,et al.  Cystic precursors to invasive pancreatic cancer , 2011, Nature Reviews Gastroenterology &Hepatology.

[16]  R. Pearson.  Magnetic Resonance Imaging Surveillance Detects Early-Stage Pancreatic Cancer in Carriers of a p16-Leiden Mutation , 2011 .

[17]  J. Stockman,et al.  Risk of Pancreatic Cancer in Families With Lynch Syndrome , 2011 .

[18]  V. Fendrich,et al.  German national case collection for familial pancreatic cancer (FaPaCa): ten years experience , 2011, Familial Cancer.

[19]  Y. Yatabe,et al.  Development of pancreatic cancers during long-term follow-up of side-branch intraductal papillary mucinous neoplasms. , 2010, Endoscopy.

[20]  K. Strauch,et al.  PALB2 mutations in European familial pancreatic cancer families , 2010, Clinical genetics.

[21]  M. Nowak,et al.  Distant Metastasis Occurs Late during the Genetic Evolution of Pancreatic Cancer , 2010, Nature.

[22]  Robert L Fine,et al.  Pancreatic Cancer Screening in a Prospective Cohort of High-Risk Patients: A Comprehensive Strategy of Imaging and Genetics , 2010, Clinical Cancer Research.

[23]  Michael Goggins,et al.  Update on familial pancreatic cancer. , 2010, Advances in surgery.

[24]  M. Falconi,et al.  Familial pancreatic cancer in Italy. Risk assessment, screening programs and clinical approach: a position paper from the Italian Registry. , 2010, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[25]  Geoffrey S. Tobias,et al.  Family history of cancer and risk of pancreatic cancer: A pooled analysis from the Pancreatic Cancer Cohort Consortium (PanScan) , 2010, International journal of cancer.

[26]  E. Kuipers,et al.  High Cancer Risk in Peutz–Jeghers Syndrome: A Systematic Review and Surveillance Recommendations , 2010, The American Journal of Gastroenterology.

[27]  Michael B Farnell,et al.  Pancreatoduodenectomy for ductal adenocarcinoma: implications of positive margin on survival. , 2010, Archives of surgery.

[28]  B. Lau,et al.  Importance of Age of Onset in Pancreatic Cancer Kindreds , 2010, Journal of the National Cancer Institute.

[29]  R. Hruban,et al.  Increased Prevalence of Precursor Lesions in Familial Pancreatic Cancer Patients , 2009, Clinical Cancer Research.

[30]  W. Foulkes,et al.  Analysis of the gene coding for the BRCA2-interacting protein PALB2 in familial and sporadic pancreatic cancer. , 2009, Gastroenterology.

[31]  D. Gouma,et al.  The Yield of First-Time Endoscopic Ultrasonography in Screening Individuals at a High Risk of Developing Pancreatic Cancer , 2009, The American Journal of Gastroenterology.

[32]  J. Heverhagen,et al.  Five years of prospective screening of high-risk individuals from families with familial pancreatic cancer , 2009, Gut.

[33]  Alison P. Klein,et al.  Exomic Sequencing Identifies PALB2 as a Pancreatic Cancer Susceptibility Gene , 2009, Science.

[34]  Laura H. Tang,et al.  BRCA germline mutations in Jewish patients with pancreatic adenocarcinoma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[35]  M. Regueiro.  Analysis of the Gene Coding for the BRCA2-Interacting Protein PALB2 in Familial and Sporadic Pancreatic Cancer , 2009 .

[36]  D. Bishop,et al.  Increased Risk of Cancer Other Than Melanoma in CDKN2A Founder Mutation (p16-Leiden)-Positive Melanoma Families , 2008, Clinical Cancer Research.

[37]  G. Guyatt,et al.  Use of GRADE grid to reach decisions on clinical practice guidelines when consensus is elusive , 2008, BMJ : British Medical Journal.

[38]  H. Iishi,et al.  Development of ductal carcinoma of the pancreas during follow-up of branch duct intraductal papillary mucinous neoplasm of the pancreas , 2008, Gut.

[39]  G. Guyatt,et al.  GRADE: an emerging consensus on rating quality of evidence and strength of recommendations , 2008, BMJ : British Medical Journal.

[40]  J. Donohue,et al.  Long-Term Survival After Pancreatoduodenectomy for Pancreatic Adenocarcinoma: Is Cure Possible? , 2008, Annals of surgery.

[41]  C. Lightdale,et al.  Interobserver agreement for EUS findings in familial pancreatic-cancer kindreds. , 2007, Gastrointestinal endoscopy.

[42]  Giovanni Parmigiani,et al.  PancPRO: risk assessment for individuals with a family history of pancreatic cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[43]  Mariza de Andrade,et al.  The Prevalence of BRCA2 Mutations in Familial Pancreatic Cancer , 2007, Cancer Epidemiology Biomarkers & Prevention.

[44]  Michael A. Choti,et al.  1423 pancreaticoduodenectomies for pancreatic cancer: A single-institution experience , 2006, Journal of Gastrointestinal Surgery.

[45]  S. Puig,et al.  Features associated with germline CDKN2A mutations: a GenoMEL study of melanoma-prone families from three continents , 2006, Journal of Medical Genetics.

[46]  H. Lynch,et al.  Pancreatic cancer and the FAMMM syndrome , 2007, Familial Cancer.

[47]  E. Fishman,et al.  Screening for early pancreatic neoplasia in high-risk individuals: a prospective controlled study. , 2006, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[48]  S. Chari,et al.  International Consensus Guidelines for Management of Intraductal Papillary Mucinous Neoplasms and Mucinous Cystic Neoplasms of the Pancreas , 2006, Pancreatology.

[49]  J. C. Houwelingen,et al.  Cancer risks in BRCA2 families: estimates for sites other than breast and ovary , 2005, Journal of Medical Genetics.

[50]  M. Canto.  Screening for pancreatic neoplasia in high-risk individuals: who, what, when, how? , 2005, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[51]  W. Greenhalf,et al.  Hereditary pancreatitis and secondary screening for early pancreatic cancer. , 2005, Roczniki Akademii Medycznej w Bialymstoku.

[52]  D. Whitcomb.  Inflammation and Cancer V. Chronic pancreatitis and pancreatic cancer. , 2004, American journal of physiology. Gastrointestinal and liver physiology.

[53]  Steven Piantadosi,et al.  Screening for pancreatic neoplasia in high-risk individuals: an EUS-based approach. , 2004, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[54]  G. Guyatt,et al.  Grading quality of evidence and strength of recommendations , 2004, BMJ : British Medical Journal.

[55]  K. Campbell,et al.  Intraductal Papillary Mucinous Neoplasms of the Pancreas: An Updated Experience , 2004, Annals of surgery.

[56]  Elizabeth Lee-Lewandrowski,et al.  Diagnosis of pancreatic cystic neoplasms: a report of the cooperative pancreatic cyst study. , 2004, Gastroenterology.

[57]  Alison P. Klein,et al.  Prospective Risk of Pancreatic Cancer in Familial Pancreatic Cancer Kindreds , 2004, Cancer Research.

[58]  A. Ziegler,et al.  BRCA2 germline mutations in familial pancreatic carcinoma. , 2003, Journal of the National Cancer Institute.

[59]  M. Kimmey,et al.  Screening and surveillance for hereditary pancreatic cancer. , 2002, Gastrointestinal endoscopy.

[60]  Douglas F Easton,et al.  Cancer Incidence in BRCA1 mutation carriers. , 2002, Journal of the National Cancer Institute.

[61]  P. Maisonneuve,et al.  Chronic Pancreatitis and Pancreatic Cancer , 2002, Digestive Diseases.

[62]  Kathleen M Murphy,et al.  Evaluation of candidate genes MAP2K4, MADH4, ACVR1B, and BRCA2 in familial pancreatic cancer: deleterious BRCA2 mutations in 17%. , 2002, Cancer research.

[63]  J. Cameron,et al.  STK11/LKB1 Peutz-Jeghers gene inactivation in intraductal papillary-mucinous neoplasms of the pancreas. , 2001, The American journal of pathology.

[64]  C. Ulrich.  Pancreatic Cancer in Hereditary Pancreatitis: Consensus Guidelines for Prevention, Screening and Treatment , 2001, Pancreatology.

[65]  R. Brand,et al.  Hereditary Pancreatic Cancer , 2001, Pancreatology.

[66]  M. Kimmey,et al.  Familial Fibrocystic Pancreatic Atrophy With Endocrine Cell Hyperplasia and Pancreatic Carcinoma , 2001, The American journal of surgical pathology.

[67]  G. Zamboni,et al.  The Immunohistochemical Mucin Expression Pattern Distinguishes Different Types of Intraductal Papillary Mucinous Neoplasms of the Pancreas and Determines Their Relationship to Mucinous Noncystic Carcinoma and Ductal Adenocarcinoma , 2001, The American journal of surgical pathology.

[68]  R H Hruban,et al.  Pancreatic Intraepithelial Neoplasia: A New Nomenclature and Classification System for Pancreatic Duct Lesions , 2001, The American journal of surgical pathology.

[69]  S. Goodman,et al.  Very high risk of cancer in familial Peutz-Jeghers syndrome. , 2000, Gastroenterology.

[70]  M. Kimmey,et al.  Early Diagnosis and Treatment of Pancreatic Dysplasia in Patients with a Family History of Pancreatic Cancer , 1999, Annals of Internal Medicine.

[71]  J. I. van der Spoel,et al.  Myocardial contusion as a result of isolated sternal fractures: a fact or a myth? , 1999, European journal of emergency medicine : official journal of the European Society for Emergency Medicine.

[72]  A. Jemal,et al.  Global cancer statistics , 2011, CA: a cancer journal for clinicians.

[73]  R. Hruban,et al.  Pancreatic adenocarcinomas with DNA replication errors (RER+) are associated with wild-type K-ras and characteristic histopathology. Poor differentiation, a syncytial growth pattern, and pushing borders suggest RER+. , 1998, The American journal of pathology.

[74]  T. Tosteson,et al.  K-ras mutation in focal proliferative lesions of human pancreas. , 1998, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[75]  R H Hruban,et al.  Progression of pancreatic intraductal neoplasias to infiltrating adenocarcinoma of the pancreas. , 1998, The American journal of surgical pathology.

[76]  E. Dimagno,et al.  Hereditary pancreatitis and the risk of pancreatic cancer. International Hereditary Pancreatitis Study Group. , 1997, Journal of the National Cancer Institute.

[77]  C. Moskaluk,et al.  Germline BRCA2 gene mutations in patients with apparently sporadic pancreatic carcinomas. , 1996, Cancer research.

[78]  F. Collins,et al.  The carrier frequency of the BRCA1 185delAG mutation is approximately 1 percent in Ashkenazi Jewish individuals , 1995, Nature Genetics.

[79]  D L Sackett,et al.  An assessment of clinically useful measures of the consequences of treatment. , 1988, The New England journal of medicine.

[80]  T. Sharpton,et al.  "Gut". , 2022, Canadian Medical Association journal.